Document Detail

Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.
MedLine Citation:
PMID:  21385928     Owner:  NLM     Status:  MEDLINE    
PURPOSE: On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention of colorectal cancer.
EXPERIMENTAL DESIGN: Randomly assigned to sulindac (300 mg daily), etodolac (400 mg daily), and placebo groups were 189 subjects without polyps or who had undergone polypectomy. Drugs were administered for 2 months. ACF in the rectal region were counted by magnifying endoscopy. Occurrence of polyps was evaluated at 12 months. A planned interim analysis was conducted.
RESULTS: ACF number at 2 months was significantly suppressed in the sulindac group (P = 0.0075), but not in the etodolac group (P = 0.73). In the sulindac group, the numbers of adenomas plus hyperplastic polyps (total polyps) and adenomas at 12 months were significantly (P = 0.02) and marginally (P = 0.064) lower, respectively, in comparison with the placebo group; no such difference was observed in the etodolac group. In analysis of only polypectomized subjects, the numbers of total polyps and adenomas in the sulindac group were even more markedly lower, with P values of 0.014 and 0.034, respectively. A similar tendency was confirmed by analyses of the incidence of polyps at 12 months. Suppression rates of total polyps and adenomas in ACF responders to sulindac were significantly greater than in nonresponders. In all groups, compliance was more than 90% and no intolerable adverse effects were observed.
CONCLUSIONS: ACF may be useful as surrogate lesions for chemoprevention of colorectal cancer.
Tetsuji Takayama; Hiroyuki Nagashima; Masahiro Maeda; Shuichi Nojiri; Michiaki Hirayama; Yoichiro Nakano; Yasuo Takahashi; Yasushi Sato; Hitoshi Sekikawa; Mitsuru Mori; Tomoko Sonoda; Tetsuo Kimura; Junji Kato; Yoshiro Niitsu
Related Documents :
21409548 - Four-year functional results of the suburethral sling procedure for stress urinary inco...
19050408 - The long-term effect of tetrabenazine in the management of huntington disease.
21147298 - Potentials and limitations of low-concentration contrast medium (150 mg iodine/ml) in c...
21242428 - Analysis of nasal ptosis correction using lower lateral to upper lateral cartilage susp...
17224498 - Long-term results of endovascular abdominal aortic aneurysm treatment with the first ge...
20662658 - Severe corneal changes following intravitreal injection of bevacizumab.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2011-03-08
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  17     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-06-03     Completed Date:  2011-12-27     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3803-11     Citation Subset:  IM    
Copyright Information:
©2011 AACR.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aberrant Crypt Foci / drug therapy*
Adenoma / drug therapy
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Colonic Polyps / pathology,  prevention & control*
Colorectal Neoplasms / drug therapy*
Etodolac / therapeutic use*
Middle Aged
Sulindac / therapeutic use*
Reg. No./Substance:
184SNS8VUH/Sulindac; 2M36281008/Etodolac

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosar...
Next Document:  Targeting the BMK1 MAP kinase pathway in cancer therapy.